Compare
Lftd Partners Inc. vs Sunshine Biopharma Inc. vs Earth Science Tech, Inc. vs Cumberland Pharmaceuticals Inc
| Latest fiscal year | Lftd Partners Inc. LIFD | Sunshine Biopharma Inc. SBFM | Earth Science Tech, Inc. ETST | Cumberland Pharmaceuticals Inc CPIX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2026-03-31 | 2025-12-31 |
| Revenue | $36.92M | $36.31M | $35.70M | $44.52M |
| Revenue growth (YoY) | -1.1% | +4.1% | +7.8% | +17.6% |
| Gross margin | 34.2% | 33.8% | 71.4% | 85.0% (computed) |
| Operating margin | 2.5% | -17.2% | n/a | -6.3% |
| Net margin | -67.3% | -16.5% | 10.2% | -6.4% |
| Net income | -$24.86M | -$5.98M | $3.63M | -$2.84M |
| EPS (Diluted) | -$1.68 | n/a | $0.012 | -$0.19 |
| Operating cash flow | $1.32M | -$5.33M | $1.94M | $4.93M |
| Free cash flow | $1.20M | -$5.51M | $1.18M | $4.83M |
| Cash & equivalents | $1.77M | n/a | $796.8K | $11.44M |
| Total assets | $19.27M | $30.08M | $8.97M | $76.82M |
| Total liabilities | $6.64M | $7.04M | $1.93M | $52.28M |
| Shareholders' equity | $12.63M | $23.04M | $7.01M | $24.88M |
| Return on year-end equity | -196.8% | -25.9% | 51.8% | -11.4% |
| Shares outstanding | 14.82M | 4.91M | 291.32M | 14.96M |
Revenue, most recent five fiscal years
| Fiscal year | Lftd Partners Inc. | Sunshine Biopharma Inc. | Earth Science Tech, Inc. | Cumberland Pharmaceuticals Inc |
|---|---|---|---|---|
| Latest | $36.92M Ended 2025-12-31 | $36.31M Ended 2025-12-31 | $35.70M Ended 2026-03-31 | $44.52M Ended 2025-12-31 |
| 1 year earlier | $37.33M Ended 2024-12-31 | $34.87M Ended 2024-12-31 | $33.12M Ended 2025-03-31 | $37.87M Ended 2024-12-31 |
| 2 years earlier | $51.61M Ended 2023-12-31 | $24.09M Ended 2023-12-31 | $11.95M Ended 2024-03-31 | $39.55M Ended 2023-12-31 |
| 3 years earlier | $57.42M Ended 2022-12-31 | $4.35M Ended 2022-12-31 | $48.5K Ended 2023-03-31 | $42.01M Ended 2022-12-31 |
| 4 years earlier | $31.66M Ended 2021-12-31 | $228.4K Ended 2021-12-31 | $14.1K Ended 2022-03-31 | $35.05M Ended 2021-12-31 |